Esther Decabooter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Esther Decabooter has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
Brent van der Heyden
Department of Oncology, Laboratory of Experimental Radiotherapy, KU Leuven, Leuven, Belgium
2 shared publications- Evelien Bogaert
Department of Radiation-Oncology, Ghent University Hospital, Ghent, Belgium
2 shared publications - Geert Pittomvils
Department of Radiation-Oncology, Ghent University Hospital, Ghent, Belgium
2 shared publications - Guido C. Hilgers
Radiotherapiegroep, Arnhem/Deventer, the Netherlands
2 shared publications Hilde Bosmans
Department of Radiology, University Hospital Gasthuisberg, Leuven, Belgium
2 shared publications- Ilaria Rinaldi
Department of Radiation Oncology (Maastro) GROW School for Oncology Maastricht University Medical Centre+ Maastricht The Netherlands
2 shared publications
Latest Publications
- Open Access
- 14 May 2026
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 221, 111597
Patient specific quality assurance: The final safety net in radiotherapy
- 14 May 2026
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 221, 111597
Open AccessPatient specific quality assurance: The final safety net in radiotherapy
- Open Access
- 2 March 2026
- Published by Elsevier in SSRN Electronic Journal
Data-driven patient treatment optimization: a large-scale retrospective analysis of pretreatment and in vivo patient-specific quality assurance
As radiotherapy techniques become increasingly complex, patient-specific quality assurance (PSQA) must evolve to detect a broad spectrum of potential failure modes across the treatment chain. This study presents a five-year retrospective analysis of an integrated PSQA framework implemented at Maastro Clinic, combining secondary dose calculations, log-file-based verification, and Electronic Portal Dosimetry (EPD) in both pretreatment and in vivo workflows. The performance of this framework was evaluated in the context of high-priority failure modes identified by the AAPM-ESTRO Failure Mode and Effects Analysis (FMEA).A total of 18,558 treatment plans were analyzed. Pretreatment secondary dose calculations identified algorithm-specific limitations, as well as discrepancies arising from unmodeled immobilization devices in the treatment planning system (TPS) and dose uncertainties due to small fields with jaw tracking. Log file and EPD pretreatment PSQA revealed additional plan transfer and deliverability issues, including rare cases of overmodulation. In vivo dose verification of 13,658 Cone Beam CT (CBCT) based fractions demonstrated that 21.19% of treatment plans exhibited at least one interfractional deviation, primarily related to patient setup, anatomical changes, or CBCT limitations. Intrafractional motion was detected in 0.50% of plans using in vivo EPD.Mapping these findings to the FMEA revealed that the combined PSQA framework effectively detected many failure modes, though limitations remained for errors rooted in TPS input data when also used for fitting PSQA dose calculation algorithms. The results underscore the value of multimodal PSQA and highlight opportunities for future enhancement e.g. using more clinically relevant evaluation metrics and dose accumulation of PSQA results.
- 2 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessData-driven patient treatment optimization: a large-scale retrospective analysis of pretreatment and in vivo patient-specific quality assurance
As radiotherapy techniques become increasingly complex, patient-specific quality assurance (PSQA) must evolve to detect a broad spectrum of potential failure modes across the treatment chain. This study presents a five-year retrospective analysis of an integrated PSQA framework implemented at Maastro Clinic, combining secondary dose calculations, log-file-based verification, and Electronic Portal Dosimetry (EPD) in both pretreatment and in vivo workflows. The performance of this framework was evaluated in the context of high-priority failure modes identified by the AAPM-ESTRO Failure Mode and Effects Analysis (FMEA).A total of 18,558 treatment plans were analyzed. Pretreatment secondary dose calculations identified algorithm-specific limitations, as well as discrepancies arising from unmodeled immobilization devices in the treatment planning system (TPS) and dose uncertainties due to small fields with jaw tracking. Log file and EPD pretreatment PSQA revealed additional plan transfer and deliverability issues, including rare cases of overmodulation. In vivo dose verification of 13,658 Cone Beam CT (CBCT) based fractions demonstrated that 21.19% of treatment plans exhibited at least one interfractional deviation, primarily related to patient setup, anatomical changes, or CBCT limitations. Intrafractional motion was detected in 0.50% of plans using in vivo EPD.Mapping these findings to the FMEA revealed that the combined PSQA framework effectively detected many failure modes, though limitations remained for errors rooted in TPS input data when also used for fitting PSQA dose calculation algorithms. The results underscore the value of multimodal PSQA and highlight opportunities for future enhancement e.g. using more clinically relevant evaluation metrics and dose accumulation of PSQA results.
- Open Access
- 10 December 2023
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 29, 100523
Survey on fan-beam computed tomography for radiotherapy: Current implementation and future perspectives of motion management and surface guidance devices
- 10 December 2023
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 29, 100523
Open AccessSurvey on fan-beam computed tomography for radiotherapy: Current implementation and future perspectives of motion management and surface guidance devices
- Open Access
- 6 December 2023
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 29, 100522
Survey on fan-beam computed tomography for radiotherapy: Imaging for dose calculation and delineation
- 6 December 2023
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 29, 100522
Open AccessSurvey on fan-beam computed tomography for radiotherapy: Imaging for dose calculation and delineation
- Open Access
- 26 July 2023
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 96 (1149) , 20230110
Clinical benefit of range uncertainty reduction in proton treatment planning based on dual-energy CT for neuro-oncological patients
Objective: Several studies have shown that dual-energy CT (DECT) can lead to improved accuracy for proton range estimation. This study investigated the clinical benefit of reduced range uncertainty, enabled by DECT, in robust optimisation for neuro-oncological patients. Methods: DECT scans for 27 neuro-oncological patients were included. Commercial software was applied to create stopping-power ratio (SPR) maps based on the DECT scan. Two plans were robustly optimised on the SPR map, keeping the beam and plan settings identical to the clinical plan. One plan was robustly optimised and evaluated with a range uncertainty of 3% (as used clinically; denoted 3%-plan); the second plan applied a range uncertainty of 2% (2%-plan). Both plans were clinical acceptable and optimal. The dose–volume histogram parameters were compared between the two plans. Two experienced neuro-radiation oncologists determined the relevant dose difference for each organ-at-risk (OAR). Moreover, the OAR toxicity levels were assessed. Results: For 24 patients, a dose reduction >0.5/1 Gy (relevant dose difference depending on the OAR) was seen in one or more OARs for the 2%-plan; e.g. for brainstem D0.03cc in 10 patients, and hippocampus D40% in 6 patients. Furthermore, 12 patients had a reduction in toxicity level for one or two OARs, showing a clear benefit for the patient. Conclusion: Robust optimisation with reduced range uncertainty allows for reduction of OAR toxicity, providing a rationale for clinical implementation. Based on these results, we have clinically introduced DECT-based proton treatment planning for neuro-oncological patients, accompanied with a reduced range uncertainty of 2%. Advances in knowledge: This study shows the clinical benefit of range uncertainty reduction from 3% to 2% in robustly optimised proton plans. A dose reduction to one or more OARs was seen for 89% of the patients, and 44% of the patients had an expected toxicity level decrease.
- 26 July 2023
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 96 (1149) , 20230110
Open AccessClinical benefit of range uncertainty reduction in proton treatment planning based on dual-energy CT for neuro-oncological patients
Objective: Several studies have shown that dual-energy CT (DECT) can lead to improved accuracy for proton range estimation. This study investigated the clinical benefit of reduced range uncertainty, enabled by DECT, in robust optimisation for neuro-oncological patients. Methods: DECT scans for 27 neuro-oncological patients were included. Commercial software was applied to create stopping-power ratio (SPR) maps based on the DECT scan. Two plans were robustly optimised on the SPR map, keeping the beam and plan settings identical to the clinical plan. One plan was robustly optimised and evaluated with a range uncertainty of 3% (as used clinically; denoted 3%-plan); the second plan applied a range uncertainty of 2% (2%-plan). Both plans were clinical acceptable and optimal. The dose–volume histogram parameters were compared between the two plans. Two experienced neuro-radiation oncologists determined the relevant dose difference for each organ-at-risk (OAR). Moreover, the OAR toxicity levels were assessed. Results: For 24 patients, a dose reduction >0.5/1 Gy (relevant dose difference depending on the OAR) was seen in one or more OARs for the 2%-plan; e.g. for brainstem D0.03cc in 10 patients, and hippocampus D40% in 6 patients. Furthermore, 12 patients had a reduction in toxicity level for one or two OARs, showing a clear benefit for the patient. Conclusion: Robust optimisation with reduced range uncertainty allows for reduction of OAR toxicity, providing a rationale for clinical implementation. Based on these results, we have clinically introduced DECT-based proton treatment planning for neuro-oncological patients, accompanied with a reduced range uncertainty of 2%. Advances in knowledge: This study shows the clinical benefit of range uncertainty reduction from 3% to 2% in robustly optimised proton plans. A dose reduction to one or more OARs was seen for 89% of the patients, and 44% of the patients had an expected toxicity level decrease.
- 9 November 2022
- Published by Elsevier in Physica Medica
- Vol. 104, 67-74
Quality assurance of scanned proton beams at different gantry angles using an ionization chamber array in a rotational phantom
- 9 November 2022
- Published by Elsevier in Physica Medica
- Vol. 104, 67-74
Quality assurance of scanned proton beams at different gantry angles using an ionization chamber array in a rotational phantom
- Open Access
- 11 June 2021
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 94 (1123) , 20210473
Operation and calibration of the novel PTW 1600SRS detector for the verification of single isocenter stereotactic radiosurgery treatments of multiple small brain metastases
Objectives: The aim of this work was to evaluate the operation of the 1600SRS detector and to develop a calibration procedure for verifying the dose delivered by a single isocenter stereotactic radiosurgery (SRS) treatment of small multiple brain metastases (BM). Methods: 14 clinical treatment cases were selected with the number of BM ranging from 2 to 11. The dosimetric agreement was investigated between the calculated and the measured dose by an OCTAVIUS 1600SRS array detector in an OCTAVIUS 4D phantom equipped with dedicated SRS top. The cross-calibration procedure deviated from the manufacturer’s as it applied field sizes and dose rates corresponding to the volumetric modulated arc therapy segments in each plan. Results: Measurements with a plan specific cross-calibration showed mean ± standard deviation (SD) agreement scores for cut-off values 50%, 80%, 95%, of 98.6 ± 1.7%, 96.5 ± 4.6%, 97.3 ± 4.4% for the 6 MV plans respectively, and 98.6 ± 1.5%, 96.6 ± 4.0% 96.4 ± 6.3%, for the 6 MV flattening filter free (FFF) plans respectively. Using the default calibration procedure instead of the plan specific calibration could lead to a combined systematic dose offset of 4.1% for our treatment plans. Conclusion: The 1600SRS detector array with the 4D phantom offers an accurate solution to perform routine quality assurance measurements of single isocenter SRS treatments of multiple BM. This work points out the necessity of an adapted cross-calibration procedure. Advances in knowledge: A dedicated calibration procedure enables accurate dosimetry with the 1600SRS detector for small field single isocenter SRS treatment of multiple brain metastases for a large amount of BM.
- 11 June 2021
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 94 (1123) , 20210473
Open AccessOperation and calibration of the novel PTW 1600SRS detector for the verification of single isocenter stereotactic radiosurgery treatments of multiple small brain metastases
Objectives: The aim of this work was to evaluate the operation of the 1600SRS detector and to develop a calibration procedure for verifying the dose delivered by a single isocenter stereotactic radiosurgery (SRS) treatment of small multiple brain metastases (BM). Methods: 14 clinical treatment cases were selected with the number of BM ranging from 2 to 11. The dosimetric agreement was investigated between the calculated and the measured dose by an OCTAVIUS 1600SRS array detector in an OCTAVIUS 4D phantom equipped with dedicated SRS top. The cross-calibration procedure deviated from the manufacturer’s as it applied field sizes and dose rates corresponding to the volumetric modulated arc therapy segments in each plan. Results: Measurements with a plan specific cross-calibration showed mean ± standard deviation (SD) agreement scores for cut-off values 50%, 80%, 95%, of 98.6 ± 1.7%, 96.5 ± 4.6%, 97.3 ± 4.4% for the 6 MV plans respectively, and 98.6 ± 1.5%, 96.6 ± 4.0% 96.4 ± 6.3%, for the 6 MV flattening filter free (FFF) plans respectively. Using the default calibration procedure instead of the plan specific calibration could lead to a combined systematic dose offset of 4.1% for our treatment plans. Conclusion: The 1600SRS detector array with the 4D phantom offers an accurate solution to perform routine quality assurance measurements of single isocenter SRS treatments of multiple BM. This work points out the necessity of an adapted cross-calibration procedure. Advances in knowledge: A dedicated calibration procedure enables accurate dosimetry with the 1600SRS detector for small field single isocenter SRS treatment of multiple brain metastases for a large amount of BM.
- 13 December 2019
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 93 (1107) , 20190598
Beam commissioning of the first compact proton therapy system with spot scanning and dynamic field collimation
Objectives: To describe the measurements and to present the results of the beam commissioning and the beam model validation of a compact, gantry-mounted, spot scanning proton accelerator system with dynamic layer-by-layer field collimation. Methods: We performed measurements of depth dose distributions in water, spot and scanned field size in air at different positions from the isocenter plane, spot position over the 20 × 20 cm2 scanned area, beam monitor calibration in terms of absorbed dose to water and specific field collimation measurements at different gantry angles to commission the system. To validate the beam model in the treatment planning system (TPS), we measured spot profiles in water at different depths, absolute dose in water of single energy layers of different field sizes and inversely optimised spread-out Bragg peaks (SOBP) under normal and oblique beam incidence, field size and penumbra in water of SOBPs, and patient treatment specific quality assurance in homogeneous and heterogeneous phantoms. Results: Energy range, spot size, spot position and dose output were consistent at all gantry angles with 0.3 mm, 0.4 mm, 0.6 mm and 0.5% maximum deviations, respectively. Uncollimated spot size (one sigma) in air with an air-gap of 10 cm ranged from 4.1 to 16.4 mm covering a range from 32.2 to 1.9 cm in water, respectively. Absolute dose measurements were within 3% when comparing TPS and experimental data. Gamma pass rates >98% and >96% at 3%/3 mm were obtained when performing 2D dose measurements in homogeneous and in heterogeneous media, respectively. Leaf position was within ±1 mm at all gantry angles and nozzle positions. Conclusions: Beam characterisation and machine commissioning results, and the exhaustive end-to-end tests performed to assess the proper functionality of the system, confirm that it is safe and accurate to treat patients. Advances in knowledge: This is the first paper addressing the beam commissioning and the beam validation of a compact, gantry-mounted, pencil beam scanning proton accelerator system with dynamic layer-by-layer multileaf collimation.
- 13 December 2019
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 93 (1107) , 20190598
Beam commissioning of the first compact proton therapy system with spot scanning and dynamic field collimation
Objectives: To describe the measurements and to present the results of the beam commissioning and the beam model validation of a compact, gantry-mounted, spot scanning proton accelerator system with dynamic layer-by-layer field collimation. Methods: We performed measurements of depth dose distributions in water, spot and scanned field size in air at different positions from the isocenter plane, spot position over the 20 × 20 cm2 scanned area, beam monitor calibration in terms of absorbed dose to water and specific field collimation measurements at different gantry angles to commission the system. To validate the beam model in the treatment planning system (TPS), we measured spot profiles in water at different depths, absolute dose in water of single energy layers of different field sizes and inversely optimised spread-out Bragg peaks (SOBP) under normal and oblique beam incidence, field size and penumbra in water of SOBPs, and patient treatment specific quality assurance in homogeneous and heterogeneous phantoms. Results: Energy range, spot size, spot position and dose output were consistent at all gantry angles with 0.3 mm, 0.4 mm, 0.6 mm and 0.5% maximum deviations, respectively. Uncollimated spot size (one sigma) in air with an air-gap of 10 cm ranged from 4.1 to 16.4 mm covering a range from 32.2 to 1.9 cm in water, respectively. Absolute dose measurements were within 3% when comparing TPS and experimental data. Gamma pass rates >98% and >96% at 3%/3 mm were obtained when performing 2D dose measurements in homogeneous and in heterogeneous media, respectively. Leaf position was within ±1 mm at all gantry angles and nozzle positions. Conclusions: Beam characterisation and machine commissioning results, and the exhaustive end-to-end tests performed to assess the proper functionality of the system, confirm that it is safe and accurate to treat patients. Advances in knowledge: This is the first paper addressing the beam commissioning and the beam validation of a compact, gantry-mounted, pencil beam scanning proton accelerator system with dynamic layer-by-layer multileaf collimation.